Table 1 Satisfaction with fertility- and sexuality-related information in 319 young breast cancer survivors

At baseline (M0)

Age, years

36.7 ± 3.7

36.7 ± 3.7

0.658

36.7 ± 3.5

0.798

French as mother-language

0.615

0.901

No

17 (5.3)

8 (47.1)

7 (41.2)

Yes

302 (94.7)

161 (53.3)

129 (42.7)

Living as a couple or having regular partner

0.152

0.126

No

41 (12.9)

26 (63.4)

22 (53.7)

Yes

278 (87.1)

143 (51.4)

114 (41.0)

Level of education

0.977

0.086

Lower than high school graduate

103 (32.3)

54 (52.4)

53 (51.5)

High school graduate

60 (18.8)

31 (51.7)

25 (41.7)

Greater than high school graduate

137 (42.9)

73 (53.3)

51 (37.2)

Missing values

19 (6.0)

Employed

0.251

0.050

No

55 (17.2)

33 (60.0)

30 (54.5)

Yes

264 (82.8)

136 (51.5)

106 (40.2)

Having children

0.446

0.911

None

50 (15.7)

29 (58.0)

21 (42.0)

One or more

259 (81.2)

135 (52.1)

111 (42.9)

Missing values

10 (3.1)

Place of residence

0.858

0.680

Rural

38 (11.9)

21 (55.3)

18 (47.4)

<200,000 inhabitants

99 (31.0)

54 (54.5)

44 (44.4)

≥200,000 inhabitants

182 (57.1)

94 (51.6)

74 (40.7)

Had opportunity to ask questions at cancer disclosure

0.002

0.041

No

56 (17.6)

19 (33.9)

17 (30.4)

Yes

263 (82.4)

150 (57.0)

119 (45.2)

Received information about disease at cancer disclosure

0.124

0.006

No

89 (27.9)

41 (46.1)

27 (30.3)

Yes

230 (72.1)

128 (55.7)

109 (47.4)

Satisfied with information about disease at cancer disclosure

0.035

0.004

No

123 (38.6)

56 (45.5)

40 (32.5)

Yes

196 (61.4)

113 (57.7)

96 (49.0)

At 10 month after diagnosis (M10): medical characteristics

Tumor stage

0.960

0.349

Stage 0

36 (11.3)

19 (52.8)

16 (44.4)

Stage I

89 (27.9)

47 (52.8)

36 (40.4)

Stage II

145 (45.5)

79 (54.5)

63 (43.4)

Stage III

44 (13.8)

22 (50.0)

21 (47.7)

Unknown

5 (1.6)

2 (40.0)

0 (0.0)

Breast surgery

0.216

0.250

Mastectomy

121 (37.9)

59 (48.8)

 57 (47.1)

Tumorectomy

195 (61.1)

109 (55.9)

 71 (40.5)

Missing values

3 (0.9)

Chemotherapy

0.769

0.752

No

70 (21.9)

36 (51.4)

31 (44.3)

Yes

249 (78.1)

133 (53.4)

105 (42.2)

FEC100 chemotherapy regimen

0.126

0.430

No

142 (44.5)

82 (57.7)

64 (45.1)

Yes

177 (55.5)

87 (49.2)

72 (40.7)

Radiotherapy

0.696

0.206

No

32 (10.0)

18 (56.3)

17 (53.1)

Yes

287 (90.0)

151 (52.6)

119 (41.5)

Trastuzumab treatment

0.728

0.185

No

259 (81.2)

136 (52.5)

115 (44.4)

Yes

60 (18.8)

33 (55.0)

21 (35.0)

Hormone treatment

0.197

0.094

No

120 (37.6)

58 (48.3)

44 (36.7)

Yes

199 (62.4)

111 (55.8)

92 (46.2)

Family history of breast or ovarian cancer

0.076

0.468

No

225 (70.5)

112 (49.8)

93 (41.3)

Yes

94 (29.5)

57 (60.6)

43 (45.7)

Report of “serious” comorbidities^a by physician

0.401

0.441

No

273 (85.6)

142 (52.0)

114 (41.8)

Yes

46 (14.4)

27 (58.7)

22 (47.8)

At 10 month after diagnosis (M10): patient questionnaire

Attention and⁄or memory problems

0.232

0.037

No

99 (31.0)

57 (57.6)

51 (51.5)

Yes

201 (63.0)

101 (50.2)

78 (38.8)

Missing values

19 (6.0)

MAC-21 score

Anxious preoccupation subscale

50.0 ± 10.0

48.3 ± 10.3

0.001

48.8 ± 10.4

0.084

Fighting spirit subscale

50.6 ± 10.0

51.9 ± 9.1

0.014

51.4 ± 9.0

0.196

Hopelessness/helplessness subscale

49.2 ± 9.6

48.3 ± 8.6

0.075

49.1 ± 8.6

0.784

At 48 month after diagnosis (M48)

Preserved fertility

0.478

0.429

No

221 (69.3)

120 (54.3)

91 (41.2)

Yes

98 (30.7)

49 (50.0)

45 (45.9)

Satisfied with medical follow-up

0.005

0.007

No

91 (28.5)

37 (40.7)

28 (30.8)

Yes

228 (71.5)

132 (57.9)

108 (47.4)

Score of sexual dysfunction (RSS subscale)

9.5 ± 4.1

9.2 ± 4.2

0.113

9.1 ± 4.2

0.110